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Visualizing and quantifying vascular endothelial growth factor (VEGF) levels are crucial factors in under-
standing the tumor environment and monitoring antiangiogenic treatment. The small peptidic probes
described by Fedorova et al. in this issue appear to be superior to antibodies in reflecting the dynamics of
VEGF as they facilitate image quantification.Angiogenesis is critical in tumor progres-
sion, and it is now widely accepted that
mutations of oncogenes and tumor sup-
pressor genes can cause a tumor to be-
come angiogenic (Bergers and Benjamin,
2003). Emerging preclinical and clinical
evidence (Niu and Chen, 2010) has
substantiated that vascular endothelial
growth factor (VEGF), a key regulator of
tumor angiogenesis, is an effective target
for the prevention and control of malig-
nancies, especially for solid tumors. The
effectiveness of antiangiogenic drugs,
however, does not always translate into
changes in tumor size, making the radio-
logical evaluation of efficacy using stan-
dardResponse EvaluationCriteria In Solid
Tumors (RECIST) and/or World Health
Organization (WHO) criteria inappropriate
(Faivre et al., 2007). Accordingly, there
are intensive investigations todevelopnon-
invasive imaging modalities that reflect
the functional and molecular changes
associated with therapeutic interventions.
Molecular imaging probes that target
VEGF or the VEGF receptor (VEGFR)
could enable new paradigms for the as-
sessment of antiangiogenic treatment
and facilitate a better understanding of
the role of VEGF/VEGFR expression pro-
files in many angiogenesis-related dis-
eases. Although VEGF receptors are
relatively accessible, it has proven very
challenging to image and understand
VEGF expression, owing to the solubility
and dynamic nature of VEGF.
So far, most VEGF-related imaging
studies have focused on immuno-single
photon emission computed tomography
(SPECT) or immuno-positron emission
tomography (PET),which haveused imag-
ing probes consisting of radiolabeledantibodies against VEGF. For example,
bevacizumab (Avastin; Roche), a human-
ized monoclonal antibody directed
against all VEGF-A isoforms, has been
labeled with 64Cu (t1/2 = 12.7 h) after
DOTA conjugation to image VEGF ex-
pression in HT29 colorectal cancer xeno-
grafts. PET imaging showed a clear
accumulation of 64Cu-DOTA-bevacizu-
mab in the tumors. In addition, tumor
accumulation of 64Cu-DOTA-bevacizu-
mab correlated well with VEGF expres-
sion, as measured by western blot anal-
ysis (Paudyal et al., 2011). In a clinical
study of 14 patients with clear cell renal
cell cancer (ccRCC) performed by Desar
et al. (2010), all five controls (i.e., those
not treated with neoadjuvant therapy)
showed a preferential tumor accumula-
tion of 111In-bevacizumab.
The expression level of VEGF within
tumor regions is much lower than that of
many other tumor markers, such as
EGFR, HER2, or integrins. Thus, it is inef-
fective to use VEGF-targeted imaging for
direct diagnosis. Rather, a more appro-
priate application of VEGF imaging has
been to monitor therapeutic responses to
antiangiogenic treatment (Desar et al.,
2010; Nagengast et al., 2011). For
example, treatment with sorafenib (Nexa-
var; Bayer), a small-molecule tyrosine
kinase inhibitor against VEGFRs, resulted
ina significantdecreaseof 111In-bevacizu-
mab uptake in ccRCC (Desar et al., 2010).
The change in VEGF levels that is in-
duced by therapeutic drugs is a very dy-
namic process. Thus, repetitive timely
imaging is critical to accurately reflect
VEGF levels in tumor environments. Unfor-
tunately, this is difficult to achieve with full-
length antibodies that are labeledwith longChemistry & Biology 18, July 29, 2011half-lived isotopes. Bevacizumab, for ex-
ample, is typically labeled with long half-
lived radioisotopes to facilitate imaging at
up to seven days after tracer injection. To
gain more insight into the dynamics of the
response of a tumor to antiangiogenic
treatment, Nagengast et al. (2011) labeled
Ranibizumab, a Fab fragment of bevacizu-
mab, with 89Zr (t1/2 = 78.4 h) for PET
imaging. Nevertheless, they still needed
up to 24 hr to obtain optimal images.
In the current issue of Chemistry &
Biology, Fedorova et al. (2011) have iden-
tified new peptide probes for VEGF
imaging using phage display techniques.
Their optimized peptide, Z-3B, showed
high binding affinity and specificity for
VEGF. Unlike common linear peptides,
which are very flexible and unstable,
Z-3B forms a very stable three helix scaf-
fold structure. The small peptide facili-
tates labeling with 18F, a radionuclide
with a short half-life of 109.8 min. For
18F-Z-3B, the optimal imaging time point
is at only 2 hr after tracer injection, com-
pared with a period of 48 to 72 hr for
PET imaging with antibodies. Fast renal
and hepatobiliary clearance resulted in
good tumor-to-blood and tumor-to-
muscle ratios of the peptide tracer. For
imaging only purposes, particularly in the
case of VEGF, small molecules with high
binding affinity and specificity would be
superior to antibodies and antibody frag-
ments. Theoretically, patients can be re-
imaged at very short intervals with such
peptidic probes, if wished, to visualize
any changes in VEGF expression at a
greater time-resolution.
To stratify patient responses to therapy,
image quantification is needed to assess
target expression or activity. For example,ª2011 Elsevier Ltd All rights reserved 819
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regions relatesmainly to target expression
and probe-target interaction. However,
other factors—such as blood flow, extrav-
ascularization of the probes, and intersti-
tial pressure—also need to be taken
into account (Niu et al., 2009). Although
111In-bevacizumab uptake in tumors de-
creased significantly after treatment with
sorafenib, based on immunohistochem-
istry data, VEGF levels did not change
accordingly. These results demonstrated
that VEGF expression is not the major
parameter that determines bevacizumab
accumulation. Other factors such as
tumor vessel characteristics appear to
be more important (Desar et al., 2010).
Small molecular peptides with a better
tissue penetration will therefore be less
affected by these factors than antibodies.
However, a nonspecific uptake into tumor
regions still exists. Indeed, although the
observed increase of tumor uptake of
18F-Z-3B correlated with the measured820 Chemistry & Biology 18, July 29, 2011 ª2levels of hVEGF, the slope of the regres-
sion line was low, indicating that the
imaging quantification still needs to be
improved to accurately reflect VEGF level
(Fedorova et al., 2011). Thus, along with
the development of probes with optimal
specificity and affinity, further improve-
ments in sensitivity and spatial/temporal
resolution of the used imaging techniques
and advanced quantification algorithm
and models are required to thoroughly
decipher the images.ACKNOWLEDGMENTS
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Many cellular processes are regulated byCa2+ signaling. In this issue ofChemistry &Biology, Phamet al. have
developed a photo-activated protein, LOVS1K, which enables the generation of local or global Ca2+ signals
through binding to the Ca2+-specific membrane channel Orai.Ca2+ regulates a variety of physiological
processes, including secretion, contrac-
tion gene transcription, cell proliferation,
and migration (Berridge et al., 2003). A
primary Ca2+ entry pathway in nonexcit-
able cells is determined by the Ca2+
release activated Ca2+ channel. Their two
limiting molecular components include
the Ca2+-sensor protein stromal interac-
tion molecule 1 (STIM1) that is located in
the endoplasmic reticulum and the Orai
channel in the plasma membrane (Hogan
et al., 2010). STIM1 senses the luminal
Ca2+ content, in that store depletion in-
duces STIM1 oligomerisation into puncta-
like structures. This in turn induces thecoupling of the cytosolic C-terminal do-
main of STIM1 with Orai1, thereby trig-
gering channel opening and Ca2+ entry
(Fahrner et al., 2009).
In the current issue of Chemistry &
Biology, Pham et al. (2011) present a
method that enables control of Ca2+ entry
through Orai1 channels via a photo-acti-
vated STIM1 protein. They utilized the
LOV2 domain of phototropin-1 to gen-
erate a photo-activated switch (Strickland
et al., 2008; Wu et al., 2009) in a fusion
protein of LOV2 that is N-terminally linked
to a cytosolic fragment of STIM1 (amino
acids 233–450), which they termed
LOVS1K. Upon a 300 ms exposure toblue light, LOVS1K relocates within sec-
onds from the cytosol onto Orai1. This
translocation is reversible within 10–30 s
in the dark, leading to LOVS1K dissocia-
tion from Orai1 in the plasma membrane,
thus allowing for repeated recruitment
by subsequent photo-stimulation.
The mechanism of this light-induced
LOVS1K relocation, as suggested by the
authors in their model, may involve a
conformational rearrangement within the
LOV2 domain that reduces the sterical
hindrance that prevents the interaction
of LOVS1K with Orai1 in the dark state.
Sterical shielding has recently been also
reported (Yu et al., 2011) for residues
